Doral Generic Name & Formulations
Mechanism of Action
Doral Dosage and Administration
Doral Boxed Warnings
Increased risk of drug-related mortality from concomitant use with opioids. Risk of CNS depressant effects and next-day impairment. Evaluate for co-morbid diagnoses before initiation. Reevaluate if insomnia fails to remit after 7–10 days of use. Depression. Suicidal tendencies. Abnormal thinking and behavioral changes. Write ℞ for smallest practical amount. Assess patient's risk for abuse, misuse, addiction prior to and during therapy. Avoid abrupt cessation. Withdraw gradually. Drug or alcohol abusers. Elderly (higher risk of falls). Debilitated. Neonatal sedation and withdrawal syndrome; monitor neonates exposed during pregnancy or labor. Pregnancy (esp. late stage). Nursing mothers: monitor infants.
Doral is well absorbed from the gastrointestinal tract; absorption half-life is ~30 minutes. Peak plasma concentration occurs at about 2 hours and is ~20 ng/mL after a 15mg dose.
Plasma protein bound: >95%.
Renal (31%), fecal (23%). Half-life: 39 hours.
Doral Adverse Reactions
Doral Clinical Trials
Doral Patient Counseling